{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:27:07Z","timestamp":1788485227128,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970294"],"award-info":[{"award-number":["81970294"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803497"],"award-info":[{"award-number":["81803497"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clinthera.2024.06.019","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T22:52:15Z","timestamp":1722034335000},"page":"644-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacogenomic Polygenic Model of Clopidogrel Predicts Recurrent Ischemic Events in Chinese Patients With Coronary Artery Disease"],"prefix":"10.1016","volume":"46","author":[{"given":"Xinyi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchang","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congxiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1443-2176","authenticated-orcid":false,"given":"Xiaoyan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.06.019_bib0001","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/MCA.0000000000000519","article-title":"Platelet pathophysiology, pharmacology, and function in coronary artery disease","volume":"28","author":"Ibrahim","year":"2017","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0002","article-title":"The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis","volume":"2014","author":"D'Ascenzo","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0003","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/clc.22094","article-title":"Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo-a systematic review","volume":"36","author":"Chen","year":"2013","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0004","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s00380-016-0927-6","article-title":"Platelet reactivity and clinical outcomes in patients using CYP3A4-metabolized statins with clopidogrel in percutaneous coronary intervention","volume":"32","author":"Park","year":"2017","journal-title":"Heart Vessels"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12959-019-0197-5","article-title":"A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease","volume":"17","author":"Warlo","year":"2019","journal-title":"Thromb J"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0006","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","volume":"20","author":"Sangkuhl","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0008","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/pharmaceutics14050915","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of clopidogrel and its four relevant metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 drug-drug-gene interaction predictions","volume":"14","author":"Loer","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0009","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1000667","article-title":"Polygenic risk scores: an overview from bench to bedside for personalised medicine","volume":"13","author":"Cross","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0011","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1038\/s41467-022-32407-9","article-title":"Pharmacogenomics polygenic risk score for drug response prediction using PRS-PGx methods","volume":"13","author":"Zhai","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0012","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurheartj\/ehac093","article-title":"A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study","volume":"43","author":"Lu","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0013","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1017\/S0033291719000618","article-title":"Pathway-based polygene risk for severe depression implicates drug metabolism in CONVERGE","volume":"50","author":"Docherty","year":"2020","journal-title":"Psychol Med"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0014","doi-asserted-by":"crossref","unstructured":"Varma A, Maharjan J, Garikipati A, et al. Early prediction of prostate cancer risk in younger men using polygenic risk scores and electronic health records. Cancer Med. 2023;12:379\u2013386. doi:10.1002\/cam4.4934","DOI":"10.1002\/cam4.4934"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0015","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.007012","article-title":"Polygenic score for \u03b2-blocker survival benefit in European ancestry patients with reduced ejection fraction heart failure","volume":"13","author":"Lanfear","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0016","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.gene.2014.12.051","article-title":"Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome","volume":"558","author":"Wang","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0017","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2006.07.007","article-title":"Impact of P-glycoprotein on clopidogrel absorption","volume":"80","author":"Taubert","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0018","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamaneurol.2018.4775","article-title":"Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack: secondary analysis of a randomized clinical trial","volume":"76","author":"Pan","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0019","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0020","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0021","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0022","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"Cavallari","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0023","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2013.05.006","article-title":"Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients","volume":"132","author":"Zhang","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0024","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.thromres.2016.10.008","article-title":"CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention","volume":"147","author":"Tang","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09537104.2017.1413178","article-title":"CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis","volume":"30","author":"Xi","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0026","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2147\/DDDT.S242167","article-title":"Impacts of CYP2C19 polymorphism and clopidogrel dosing on in-stent restenosis: a retrospective cohort study in Chinese patients","volume":"14","author":"Zhang","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0027","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for cyp2c19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0028","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/a-0622-8110","article-title":"P2Y12 polymorphisms and the risk of adverse clinical events in patients treated with clopidogrel: a meta-analysis","volume":"69","author":"Zhao","year":"2019","journal-title":"Drug Res (Stuttg)"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0029","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5551\/jat.33290","article-title":"Association of cytochrome P450 genetic variants with clopidogrel resistance and outcomes in acute ischemic stroke","volume":"23","author":"Yi","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ehjcvp\/pvz045","article-title":"Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients","volume":"6","author":"Lewis","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0031","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0032","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0033","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2023.05.023","article-title":"Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y12 inhibitors","volume":"228","author":"Xi","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0034","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2019.12.016","article-title":"Platelet-derived miRNAs as determinants of the antiplatelet response in clopidogrel-treated patients with ACS","volume":"186","author":"Liu","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2024.06.019_bib0035","doi-asserted-by":"crossref","first-page":"34570","DOI":"10.1038\/srep34570","article-title":"The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"}],"updated-by":[{"DOI":"10.1016\/j.clinthera.2025.06.019","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000}}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824001942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824001942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T02:44:35Z","timestamp":1757645075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824001942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0149291824001942"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.019","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.clinthera.2025.06.019","asserted-by":"object"}]},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomic Polygenic Model of Clopidogrel Predicts Recurrent Ischemic Events in Chinese Patients With Coronary Artery Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}